Prostate cancer screening with prostate-specific antigen in hemodialysis patients.
The diagnostic validity of prostate-specific antigen (PSA) among men receiving hemodialysis (HD) has not been well defined. The aim of this study was to evaluate PSA levels in HD men and to compare them with those of non-uremic controls. PSA levels were measured in 620 HD men (40-89 years old, mean age 62.4 years). In patients with PSA >4.1 ng/ml, prostate biopsies were performed. Cancer-free men were defined as having PSA ranging between 0 and 4.0 ng/ml, or PSA >4.1 ng/ml but with a pathologically negative biopsy. The resulting data was compared with that for 3,636 non-uremic controls (55-59- (n = 468), 60-69- (n = 2,220), and 70-79-year-old men (n = 948)). Of 45 HD men with PSA >4.1 ng/ml, 22 consented to undergo a biopsy. Ten were positive and 12 were negative. The mean PSA of cancer-free HD men of 50-59 (n = 159), 60-69 (n = 214), 70-79 (n = 116), and 80-89 (n = 30) were 1.0, 1.0, 1.3, and 2.1 ng/ml, respectively. Cancer-free HD men demonstrated significantly lower PSA compared to controls. HD men had lower PSA levels than those of controls.